Press Releases
-
Phastar Appoints Graham Clark as New Chief Executive Officer
Phastar Appoints Graham Clark as New Chief Executive Officer Phastar Sets Course for Further Growth with New CEO Appointment
Aug 9, 2023
-
ICS/ICB leaders Penny Dash and Paul Miller announced as speakers for the NHS Transformation Symposium
Mtech Access has announced that its annual NHS Transformation Symposium, this September, will feature guest speakers Penny Dash and Paul Miller, who hold strategic leadership roles in an Integrated Care Systemand Board, respectively.
Aug 8, 2023
-
RBQMLive, Sponsored by CluePoints, Wins Prestigious Sales and Marketing Award
RBQMLive, Sponsored by CluePoints, Wins Prestigious Sales and Marketing Award Two-day educational conference tops the experiential/event marketing category at the Sales and Marketing Technology Awards 2023
Aug 8, 2023
-
Huateng Pharma Develops CAS NO.156-83-2 (Minoxidil Intermediate) Against Hair Loss
About Huateng Pharma Huateng Pharma is a global provider in contract development and manufacturing for intermediates. With our focus on operational excellence, and the integration of manufacturing operations with EHS, quality assurance, quality control, regulatory, supply chain management and project management, we can manufacture, scale-up and supply high-quality intermediates and APIs from our China facility. Contact us Hunan Huateng Pharmaceutical Co. Ltd. Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China Email: sales@huatengusa.com Website: https://us.huatengsci.com Zip code: 410205 Telephone: +86 731 89916275 Fax: +86 0731-82251112-818
Aug 8, 2023
-
iotaSciences appoints Dr. Michael Lutz as new Chief Executive Officer
iotaSciences has announced today the appointment of Dr. Michael Lutz as CEO and Director for Iota Sciences Ltd.
Aug 7, 2023
-
Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress
Kiora Pharmaceuticals of Encinitas announced a sharpened focus on its KIO-310 vision-restoring treatments for retinal diseases. This is based largely on preliminary results observed in a recent ABACUS Phase 1b clinical trial that indicates the possibility KIO-310 could treat Retinitis Pigmentosa, Choroideremia, and Stargardt’s Disease.
Aug 7, 2023
-
United BioSource, LLC Selects Oracle Cloud Safety Technology for its Safety Programs
United BioSource, LLC (UBC), the leading provider of evidence-based research for the biopharma industry, has migrated its safety functions from on-premises to Oracle Argus Cloud Service, a trusted safety case management solution. UBC specializes in generating real-world evidence of product effectiveness, safety, and value that enable emerging and leading pharmaceutical companies to make medicine and specialty therapies safer and more accessible.
Aug 3, 2023
-
Dr. Vince Clinical Research Joins the Fight Against the Fentanyl Crisis, Announces Screening of First Subject for Cessation Therapeutics’ Overdose Prevention Therapy in a First-In-Human Trial
Dr. Vince Clinical Research (DVCR), a full-service CRO specializing in Phase I-II clinical trials, announced today the first subject was screened for Cessation Therapeutics’ CSX-1004 in a First-In-Human single ascending dose study in normal healthy volunteers. CSX-1004 is a human monoclonal antibody infusion that is being developed for the prevention of fentanyl overdose.
Aug 1, 2023
-
Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment
Kiora Pharmaceuticals and the Choroideremia Research Foundation (located in Springfield MA) have partnered to advance a potential new treatment for patients with choroideremia (CHM), a rare, inherited retinal disease that causes blindness. This collaboration will accelerate Kiora's development of a small molecule designed to restore vision in patients with later-stage retinal degeneration. Key Takeaways: Patients with CRM are often initially misdiagnosed with retinitis pigmentosa (RP), as these two conditions have similar symptoms. People with CHM can expect their peripheral vision to get worse over time, leaving only central vision. Eventually, the condition may progress to blindness. There isn't a cure but the partnership between Kiora and CRF could eventually help restore vision. CRF will assist Kiora with access to clinical and scientific thought leaders to assist in further development of KIO-301, a small molecule designed to restore vision in patients with later-stage retinal degeneration. CRF will also provide aid in enrollment of patients for any future trials of KIO-301.
Aug 2, 2023
-
SYGNATURE DISCOVERY ACCELERATES GLOBAL GROWTH WITH MAJOR NORTH AMERICAN ACQUISITION
Leading integrated drug discovery partner, Sygnature Discovery (“Sygnature”) has announced its acquisition of one of North America’s largest discovery Contract Research Organisations, Canada-based NuChem Sciences. This acquisition cements Sygnature as one of the world’s largest players in integrated drug discovery phase solutions and advances their vision to become the global market leader.
Aug 1, 2023
-
Expert Speaker Lineup Revealed for Award Winning RBQM Event
Expert Speaker Lineup Revealed for Award Winning RBQM Event Full agenda and keynote speakers announced for industry-leading risk-based quality management event focusing on the global transformation and evolution of RBQM, sponsored by CluePoints.
Jul 31, 2023
-
The Portrait Project gives clinical trial patients a platform to share their unique experiences and influence change
The Portrait Project gives clinical trial patients a platform to share their unique experiences and influence change Clinical trial participants, caregivers and health professionals share unfiltered accounts of their personal health journeys and provide insights into their experience in clinical trials.
Jul 31, 2023
-
Adaptive Research Appoints Kristin Andruska, MD, PhD as Senior Medical Director and Clinical Neuroscience & Scientific Research Director
Adaptive Research, an organization committed to democratizing clinical trials by providing full-service support to trial investigators in community settings, is pleased to announce Kristin Andruska, MD, PhD has been appointed Senior Medical Director of Clinical Neuroscience and Scientific Research Director.
Jul 24, 2023
-
TransCure bioServices expands reach into APAC with Preclina Inc partnership
TransCure bioServices has expanded its reach in the APAC region by signing a strategic partnership with leading South Korean preclinical research company Preclina Inc.
Jul 24, 2023
-
BioIVT to Discuss its Pivotal Role in Liquid Biopsy Research at the AACC Annual Scientific Meeting and Clinical Lab Expo
BioIVT’s standardized collection protocols and diverse donor base help facilitate molecular biomarker validation and ensure their clinical utility.
Jul 20, 2023
-
Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis
TVM Capital Life Science together withTillotts Pharma has announced that the companies will jointly invest up to USD 28 million in the newly formed U.S.-based biotechnology company, Mage Biologics Inc.
Jul 19, 2023
-
PrecisionLife Identifies First Detailed Genetic Risk Factors for Long COVID and Common Mechanisms with ME/CFS and other Complex Diseases
PrecisionLife has announced the results of its long COVID study, providing the first detailed genetic insights into the condition and its commonalities with other diseases.
Jul 17, 2023
-
Vector Laboratories Acquires Quanta BioDesign to Continue Growth Strategy of Strengthening Development and Manufacturing Services for Life Science and Biopharma Customers Acquisition expands customers' ability to accelerate their advanced bioconjugate
Vector Laboratories, the pioneer of innovative proteomic and glycomic research solutions, today announced the acquisition of Quanta BioDesign, the inventor of discrete polyethylene glycol (dPEG®) technology for advanced bioconjugate and payload delivery design for life science and biopharma applications
Jul 16, 2023
-
Lonza Launches TheraPRO® CHO Media System to Improve Productivity and Quality in Therapeutic Protein Manufacture
Lonza has launched the TheraPRO® CHO Media System, a new cell culture platform that simplifies processes and optimizes productivity and protein quality when used with GS-CHO cell lines.
Jul 16, 2023
-
BioIVT Acquires PrecisionMed, a Leading Global Provider of Biospecimens for Neurology and Oncology Research
PrecisionMed developed and manages the largest, private, global repository of longitudinally collected human cerebrospinal fluid (CSF) samples for scientific research.
Jul 17, 2023
